ARK Genomic is selling for under 4.41 as of the 30th of December 2025; that is No Change since the beginning of the trading day. The etf's lowest day price was 4.41. ARK Genomic has hardly any chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. The performance scores are derived for the period starting the 30th of November 2025 and ending today, the 30th of December 2025. Click here to learn more.
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in ARK Genomic. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
The output start index for this execution was zero with a total number of output elements of sixty-one. Cosh Values Of ARK Genomic Price Series is a hyperbolic price transformation function.
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ARK Genomic etf to make a market-neutral strategy. Peer analysis of ARK Genomic could also be used in its relative valuation, which is a method of valuing ARK Genomic by comparing valuation metrics with similar companies.